Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews.
News
ACR20 Day 3.1 Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.
ACR20 Day 2.3 Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.
ACR20 Day 3.2 Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in for faculty reports and overviews.
Content covered includes:
ACR20 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
ACR20 Day 1.2 Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews.
Decreasing immunogenicity, improving efficacy of pegloticase in gout
At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.
Outcomes Switching to Monotherapy: SEAM-RA Trial
Combination therapy with biologic and conventional DMARDs can be highly effective at inducing remission in patients with RA. Once controlled, patients are often interested in stopping combination drug therapy due to concerns related to medication burdens, side effect profiles, or safety.
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
ACR20 - Opening Day Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews.
